In CLL, an in vitro drugs screening revealed increased sensitivity to MEK (selumetinib, cobimetinib, trametinib) and ERK (SCH772984) inhibitors among tri12 and KRAS mutated cells [189]. Here, MAP2K7 is linked to B-cell chronic lymphocytic leukemia.